Search | IOVS | ARVO Journals

Showing 1 – 20 of 26

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2024

Photoreceptor structure following gene therapy in CNGA3 -mediated Achromatopsia: adaptive optics imaging results from a Phase 1/2 dose escalation clinical trial for AGTC-402 (rAAV2tYF-PR1.7-hCNGA3)

Yu You Jiang; Peiluo Xu; Christine Nichols Kay; Robert Sisk; Rachel M Huckfeldt; Jason Comander; Byron L Lam; Ninel Z. Gregori; Audina Berrocal; Mark E Pennesi; Andreas K Lauer; Amy Christenson; Nadia K Waheed; Jessica Ijams Wolfing Morgan

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):3289.

ARVO Annual Meeting Abstract June 2024

Subretinal gene therapy AGTC-501 for X-linked retinitis pigmentosa in the Phase 1/2 Horizon study: Post-hoc analysis of microperimetry results in the high dose groups

David G Birch; Andreas K Lauer; Paul Yang; Robert Sisk; Rajiv Anand; Darin Curtiss; Amy Christenson; Nadia K Waheed

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):2133.

ARVO Annual Meeting Abstract June 2023

Clinical and Characteristic Findings in Children diagnosed with Blue Cone Monochromacy Secondary to Locus Control Region Deletion

Preston Land; Jillian Eltzroth; Terry Schwartz; Diana Brightman; Virginia Miraldi Utz; Robert Sisk

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):4535.

ARVO Annual Meeting Abstract June 2023

Subretinal Delivery of RGX-314: A Gene Therapy for Neovascular Age-Related Macular Degeneration (nAMD)

Robert Sisk

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):5061.

ARVO Annual Meeting Abstract June 2022

Findings on visual photosensitivity in two phase 1/2 clinical trials of subretinal gene therapy with AGTC-401 and AGTC-402 for CNGB3 and CNGA3 achromatopsia

Rachel M Huckfeldt; Jason Comander; Mark E Pennesi; Paul Yang; Andreas Lauer; Robert Sisk; Edward Averbukh; Eyal Banin; Ninel Z Gregori; Janet L Davis; Byron L Lam; Christine Nichols Kay; Jessica Ijams Wolfing Morgan; Joseph Carroll; Bright Senyo Ashimatey; Matthew Feinsod

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):450.

ARVO Annual Meeting Abstract June 2022

Interim Safety Results in Two Phase 1/2 Open-label, Dose-escalation Clinical Trials of Subretinal Gene Therapy with AGTC-401 (rAAV2tYF-PR1.7-hCNGB3) and AGTC-402 (rAAV2tYF-PR1.7-hCNGA3) in Subjects with Achromatopsia (ACHM)

Alessandro Iannaccone; Mark E Pennesi; Paul Yang; Andreas Lauer; Robert Sisk; Ninel Z Gregori; Janet L Davis; Byron L Lam; Christine Nichols Kay; Mauro Goldbaum; Bright Senyo Ashimatey; Feng Zhu; Matthew Feinsod; Lejla Vajzovic

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):2829 – A0345.

ARVO Annual Meeting Abstract June 2022

18 Month Analysis of Macular Structure using Optical Coherence Tomography (OCT) from a Phase 1/2 Clinical Study of Subretinal Gene Therapy Drug AGTC-501 for X-Linked Retinitis Pigmentosa

Paul Yang; Andreas Lauer; Mark E Pennesi; David G Birch; Rand Spencer; Robert Sisk; Alessandro Iannaccone; Matthew Feinsod; Mauro Goldbaum

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):4399 – F0078.

ARVO Annual Meeting Abstract June 2022

Classification and growth rate of retinal atrophy after voretigene neparvovec-rzyl for RPE65-mediated retinal dystrophy

Nikhil Bommakanti; Benjamin Young; Robert Sisk; Audina M. Berrocal; Jacque L Duncan; Benjamin Bakall; Marc Mathias; Aaron Nagiel; Cagri G Besirli

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):456.

ARVO Annual Meeting Abstract June 2022

Alternative therapy in pediatric chronic anterior uveitis refractory to methotrexate, adalimumab and infliximab

Sheila T Angeles-Han; Virginia Miraldi Utz; Najima Mwase; Amy Cassedy; Theresa Hennard; Hermine Brunner; Eniolami Dosunmu; Alexei Grom; Michael Henrickson; Jennifer Huggins; Sarah Lopper; Daniel Lovell; Robert Sisk; Tracy Ting; Adam Kaufman

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):3189 – A0415.

ARVO Annual Meeting Abstract June 2021

Twelve-month Findings from Two Phase 1/2 Clinical Studies of Subretinal Gene Therapy Drugs for Achromatopsia

Mark E Pennesi; Paul Yang; Andreas Lauer; Robert A Sisk; Jason M Comander; Rachel M. Huckfeldt; Edward Averbuhk; Eyal Banin; Ninel Gregori; Janet L Davis; Byron L Lam; Christine Kay; Erin Leone; Deanine Halliman; Nnenna Ihekoromadu; Matthew Feinsod

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):3321.

ARVO Annual Meeting Abstract June 2021

Perifoveal Chorioretinal Atrophy Following Subretinal Injection of Voretigene Neparvovec-rzyl for RPE65-mediated Leber Congenital Amaurosis

William S Gange; Robert A Sisk; Cagri G Besirli; Thomas C Lee; Mark Borchert; Jesse Sengillo; Carlos Mendoza; Audina M Berrocal; Aaron Nagiel

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):3292.

ARVO Annual Meeting Abstract June 2021

Six Month Findings from a Phase 1/2 Clinical Study of Subretinal Gene Therapy Drug AGTC-501 for X-Linked Retinitis Pigmentosa Show Clinically Meaningful Improvement in Macular Sensitivity

Paul Yang; Andreas Lauer; Mark E Pennesi; David G Birch; rand spencer; Robert A Sisk; Alessandro Iannaccone; Erin Leone; Deanine Halliman; Nnenna Ihekoromadu; Matthew Feinsod

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1481.

Retina November 2019

Homozygous Variant in ARL3 Causes Autosomal Recessive Cone Rod Dystrophy

PDF

Shakeel A. Sheikh; Robert A. Sisk; Cara R. Schiavon; Yar M. Waryah; Muhammad A. Usmani; David H. Steel; John A. Sayer; Ashok K. Narsani; Robert B. Hufnagel; Saima Riazuddin; Richard A. Kahn; Ali M. Waryah; Zubair M. Ahmed
TAGS: autosomal recessive inheritance, family, homozygote, mutation, phenotype, progressive cone-rod dystrophy, proteins, retinitis pigmentosa
Invest. Ophthalmol. Vis. Sci.. 2019; 60(14):4811-4819. https://doi.org/10.1167/iovs.19-27263

Includes: Supplemental Content

ARVO Annual Meeting Abstract July 2019

Variants in myelin regulatory factor ( MYRF) cause autosomal dominant nanophthalmos.

Lev Prasov; Sarah J Garnai; Michelle Brinkmeier; Ben Emery; Tomas S Aleman; Louise C Pyle; Biliana O Veleva-Rotse; Robert Sisk; Sayoko Eileen Moroi; Steven M Archer; Laurel Wiinikka-Buesser; Frank W Rozsa; Gregory L Skuta; Sally Camper; Julia Richards

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):5420.

ARVO Annual Meeting Abstract July 2018

Intravitreal Anti-VEGF Injections for Exudative Retinal Arterial Macroaneurysms: Results of an International Multicenter Study

Julia Sein; Ahmad Mansour; Roberto E E Foster; Roberto Gallego-Pinazo; Marilita M Moschos; Robert Sisk; Jay Chhablani; Duangnate Rojanaporn; Tharikarn Sujirakul; Luiz Lima; Lihteh Wu; Abdulrazzak Charbaji; Hana Mansour; Yogin Patel; Sankeert Gangakhedkar; J Fernando Arevalo

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):4284.

ARVO Annual Meeting Abstract June 2017

Ocular vascular occlusion: a diagnostic window to thrombophilia and thrombotic events

Frini Makadia; Ilana Schlam; Matan Rothschild; Robert Hutchins; Robert Sisk; Ping Wang; Charles J Glueck

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):3658.

ARVO Annual Meeting Abstract September 2016

Variable expression of TIMP3 -related maculopathy due to an atypical mutation in a large family

Jerry Lee; Robert Sisk; Courtney Linne; Laura Krueger; Scott Schoenberger; Lars Fritsche; Emily Y Chew; Brian Patrick Brooks; Anita Agarwal; Zubair Ahmed; Robert B Hufnagel

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):3145.

ARVO Annual Meeting Abstract September 2016

Influence of Risk Alleles for Age-Related Macular Degeneration on Recessive Stargardt Disease Phenotypes

Robert Sisk; Robert B Hufnagel; Brent Zanke; Zubair Ahmed

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):3164.

ARVO Annual Meeting Abstract September 2016

Survey of ophthalmic and systemic features in patients with PNPLA6 -related disorders

Robert B Hufnagel; Sarah Hull; Jose Luiz Pedroso; Shuan Dai; Andrea Nemeth; Helene Dollfus; Brian Patrick Brooks; Robert Sisk; Michel Michaelides; Anthony T Moore; Zubair Ahmed

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):6564.

Visual Psychophysics and Physiological Optics July 2016

Cone Photoreceptor Structure in Patients With X-Linked Cone Dysfunction and Red-Green Color Vision Deficiency

PDF

Emily J. Patterson; Melissa Wilk; Christopher S. Langlo; Melissa Kasilian; Michael Ring; Robert B. Hufnagel; Adam M. Dubis; James J. Tee; Angelos Kalitzeos; Jessica C. Gardner; Zubair M. Ahmed; Robert A. Sisk; Michael Larsen; Stacy Sjoberg; Thomas B. Connor; Alfredo Dubra; Jay Neitz; Alison J. Hardcastle; Maureen Neitz; Michel Michaelides; Joseph Carroll
TAGS: color vision defect, pathophysiology, retinal cone, x-linked inheritance, mosaicism, phenotype
Invest. Ophthalmol. Vis. Sci.. 2016; 57(8):3853-3863. https://doi.org/10.1167/iovs.16-19608

Includes: Supplemental Content

1 2

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Photoreceptor structure following gene therapy in CNGA3 -mediated Achromatopsia: adaptive optics imaging results from a Phase 1/2 dose escalation clinical trial for AGTC-402 (rAAV2tYF-PR1.7-hCNGA3)

Subretinal gene therapy AGTC-501 for X-linked retinitis pigmentosa in the Phase 1/2 Horizon study: Post-hoc analysis of microperimetry results in the high dose groups

Clinical and Characteristic Findings in Children diagnosed with Blue Cone Monochromacy Secondary to Locus Control Region Deletion

Subretinal Delivery of RGX-314: A Gene Therapy for Neovascular Age-Related Macular Degeneration (nAMD)

Findings on visual photosensitivity in two phase 1/2 clinical trials of subretinal gene therapy with AGTC-401 and AGTC-402 for CNGB3 and CNGA3 achromatopsia

Interim Safety Results in Two Phase 1/2 Open-label, Dose-escalation Clinical Trials of Subretinal Gene Therapy with AGTC-401 (rAAV2tYF-PR1.7-hCNGB3) and AGTC-402 (rAAV2tYF-PR1.7-hCNGA3) in Subjects with Achromatopsia (ACHM)

18 Month Analysis of Macular Structure using Optical Coherence Tomography (OCT) from a Phase 1/2 Clinical Study of Subretinal Gene Therapy Drug AGTC-501 for X-Linked Retinitis Pigmentosa

Classification and growth rate of retinal atrophy after voretigene neparvovec-rzyl for RPE65-mediated retinal dystrophy

Alternative therapy in pediatric chronic anterior uveitis refractory to methotrexate, adalimumab and infliximab

Twelve-month Findings from Two Phase 1/2 Clinical Studies of Subretinal Gene Therapy Drugs for Achromatopsia

Perifoveal Chorioretinal Atrophy Following Subretinal Injection of Voretigene Neparvovec-rzyl for RPE65-mediated Leber Congenital Amaurosis

Six Month Findings from a Phase 1/2 Clinical Study of Subretinal Gene Therapy Drug AGTC-501 for X-Linked Retinitis Pigmentosa Show Clinically Meaningful Improvement in Macular Sensitivity

Homozygous Variant in ARL3 Causes Autosomal Recessive Cone Rod Dystrophy

Variants in myelin regulatory factor ( MYRF) cause autosomal dominant nanophthalmos.

Intravitreal Anti-VEGF Injections for Exudative Retinal Arterial Macroaneurysms: Results of an International Multicenter Study

Ocular vascular occlusion: a diagnostic window to thrombophilia and thrombotic events

Variable expression of TIMP3 -related maculopathy due to an atypical mutation in a large family

Influence of Risk Alleles for Age-Related Macular Degeneration on Recessive Stargardt Disease Phenotypes

Survey of ophthalmic and systemic features in patients with PNPLA6 -related disorders

Cone Photoreceptor Structure in Patients With X-Linked Cone Dysfunction and Red-Green Color Vision Deficiency

To View More...

You must be signed into an individual account to use this feature.